Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples